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Abstract In LLC-PK1 kidney epithelial cells, a 5-h pretreat-
ment with glyceryl trinitrate (GTN) resulted in substantial
desensitization of the intracellular cyclic GMP response to a
subsequent 10-min challenge with GTN (1 WM). GTN-tolerant
cells were fully sensitive to the spontaneous nitric oxide (NO)
donor spermine NONOate, which does not require enzymatic
bioactivation. Cyclic GMP stimulation by GTN was up to 3.1-
fold higher when vitamin C (1^10 mM) was present during the
pretreatment period. In contrast, other oxygen radical scaven-
gers such as tiron or dimethylsulfoxide and the NO scavenger
PTIO left tolerance induction unaltered. Together, our results
suggest that reactive oxygen species or NO do not contribute to
the development of nitrate tolerance. Tolerance reduction by
vitamin C may be due to a stabilizing effect on enzymes involved
in the bioconversion of GTN to NO.
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1. Introduction
Nitric acid esters such as glyceryl trinitrate (GTN) have
been used for more than one hundred years in the therapy
of myocardial ischemia and its principal symptom angina pec-
toris. The cellular mechanism underlying the antianginal e¡ect
of organic nitrates involves bioactivation of, and nitric oxide
(NO) release from, these compounds which have therefore
been coined NO prodrugs or NO donors. NO then activates
soluble guanylyl cyclase which generates the vasodilatory sec-
ond messenger cyclic GMP [1^3].
Sustained treatment of cardiovascular diseases with organic
nitrates has long been known to induce tolerance to the he-
modynamic and anti-ischemic e¡ects of these drugs in humans
and animals [4^6]. Despite its ¢rst description early this cen-
tury, nitrate tolerance still poses an unsolved serious clinical
problem with the basic mechanisms being only ill de¢ned.
Several lines of evidence point to down-regulation of enzy-
matic NO release from organic nitrates as being responsible
for their diminished antianginal and vasodilatory action. [7^
9]. Furthermore, irreversible blockade of the NO-sensitive
soluble guanylyl cyclase has been demonstrated under condi-
tions of nitrate tolerance [10,11]. Recently, it has been shown
that prolonged exposure of rabbits to GTN is associated with
enhanced superoxide production in the blood vessel wall [12]
suggesting that oxidative stress may cause vascular desensiti-
zation to nitrates. In agreement with this hypothesis, co-ad-
ministration of GTN and vitamin C in vivo has been found to
counteract the development of tolerance [13,14]. However,
con£icting results have been published as to whether antiox-
idants in general are capable of inhibiting vascular tolerance
[15,16] leaving open the question of possible mechanisms
underlying tolerance and tolerance reversal by vitamin C.
Using a cultured kidney epithelial cell line (LLC-PK1), the
present study investigates whether vitamin C as well as other
antioxidants/radical scavengers are capable of reducing toler-
ance induction to GTN with respect to intracellular cyclic
GMP accumulation. LLC-PK1 cells have been established as
a model for studying molecular mechanisms and pathways
involved in organic nitrate-induced activation and desensitiza-
tion of the guanylyl cyclase/cyclic GMP system [7,17].
2. Methods
2.1. Materials
LLC-PK1 cells (ATCC CL 101) were obtained from the American
Type Culture Collection (Rockville, MD, USA). Fetal calf serum,
Ham’s F-12 medium and penicillin-streptomycin were purchased
from Gibco (Eggenstein, Germany). GTN was a gift from Schwarz
Pharma AG (Monheim, Germany). 1,2-Dihydroxybenzene-3,5-disul-
fonate (tiron), vitamin C and all other reagents were obtained from
Sigma (Deisenhofen, Germany). 2-Phenyl-4,4,5,5-tetramethylimidazo-
line-1-oxyl-3-oxide (PTIO) and spermine NONOate (Sper/NO) were
obtained from Alexis Deutschland GmbH (Gruºnberg, Germany).
2.2. Cell culture
LLC-PK1 cells were maintained and subcultured in Ham’s F-12
medium, supplemented with 15% fetal calf serum, 100 U/ml penicillin
and 100 Wg/ml streptomycin. The cells were grown in a humidi¢ed
incubator at 37‡C and 5% CO2.
2.3. Incubation procedure and cyclic GMP determination
Cells grown to con£uence in 35-mm culture dishes were washed
twice with phosphate-bu¡ered saline. Cells were preincubated for 5 h
with 1 ml of a basal salt solution containing (mM): NaCl, 130;
KCl, 5.4; CaCl2, 1.8; MgCl2, 0.8; glucose, 5.5; and HEPES-NaOH,
20, bu¡ered to pH 7.3) in the presence or absence of GTN (1 WM) and
vitamin C, tiron, DMSO or PTIO. After the preincubation period,
cells were washed twice with 2 ml phosphate bu¡ered saline and in-
cubated with the basal salt solution containing isobutylmethylxan-
thine (0.5 mM). After 10 min, GTN was added and the incubation
was continued for another 10 min. The ¢nal assay volume was 1 ml.
Supernatants were aspirated and cyclic GMP levels were determined
by radioimmunoassay after addition of ethanol to the cells and sub-
sequent evaporation as previously described [18].
3. Results
A 5-h preincubation of cells with GTN (1 WM) substantially
reduced cyclic GMP elevation upon a subsequent 10-min ex-
posure to 1 WM GTN (Fig. 1). However, GTN-tolerant cells
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were fully responsive to Sper/NO (Fig. 1). Simultaneous in-
cubation with vitamin C (1 and 10 mM) attenuated tolerance
induction by GTN (Fig. 2). This e¡ect was concentration-
dependent in that 10 mM vitamin C allowed a signi¢cantly
higher cyclic GMP stimulation by GTN in tolerant cells than
1 mM vitamin C (P6 0.05; ordinary one-way ANOVA plus
Bonferroni test). Moreover, and as an additional control ex-
periment, a 5-h incubation with vitamin C (1 and 10 mM) did
not alter basal or GTN-induced cyclic GMP levels in non-
tolerant cells (Fig. 2). Intracellular cyclic GMP concentrations
in tolerant, vitamin C-treated cells did not di¡er from the
respective vehicle-treated tolerant control at the end of the
GTN-pretreatment period (data not shown). In cells pre-
treated with a combination of vitamin C and GTN, subse-
quent cyclic GMP-stimulation by GTN was 3.1-fold higher
than in cells pretreated with GTN alone (Fig. 3). Under the
same conditions, the intracellular superoxide anion scavenger
tiron (10 mM) failed to attenuate nitrate tolerance (Fig. 3).
Likewise, the intracellular scavenger of hydroxyl radicals and
peroxynitrite DMSO (0.2% v/v) and the speci¢c NO scavenger
PTIO (30 WM) were without e¡ect on the development of
nitrate tolerance (Fig. 3).
4. Discussion
The present study demonstrates attenuation of tolerance
development to GTN by concurrent administration of vitamin
C, whereas di¡erent oxygen and nitrogen radical scavengers
failed to prevent GTN-induced desensitization of the cyclic
GMP response. In control experiments, vitamin C did not
change basal or GTN-induced cyclic GMP accumulation in
non-tolerant cells. Moreover, vitamin C had no in£uence on
cyclic GMP levels in tolerant cells when measured immedi-
ately after tolerance induction, i.e. prior to the rechallenge
with GTN. Since vitamin C was washed out after the 5-h
pretreatment period, preservation of the cyclic GMP response
in tolerant cells by vitamin C cannot be due to increased
extracellular metabolism of GTN during the 10-min stimula-
tion period. Together, these data preclude a direct stimulatory
e¡ect of vitamin C on soluble guanylyl cyclase and argue
against facilitation of non-enzymatic NO release from GTN
via a chemical reaction with vitamin C. Our ¢ndings rather
suggest that vitamin C reduces tolerance by interacting at a
site upstream of NO-dependent guanylyl cyclase activation,
which might be the enzymatic bioconversion of GTN to
NO. That tolerance speci¢cally a¡ects NO release from nitric
acid esters and leaves NO sensitivity of guanylyl cyclase un-
impaired is further supported by our observation demonstrat-
ing an unaltered cyclic GMP response to spermine NONOate
in GTN-tolerant cells. NO release from spermine NONOate
occurs spontaneously in aqueous solution and does not re-
quire enzymatic catalysis [3].
According to previous studies, redox-active enzymes such as
cytochrome P-450 play a crucial role in mediating NO release
from GTN and appear to be down-regulated in tolerant vas-
cular tissue [18^21]. Interestingly, NO at high concentrations
has been shown to directly block cytochrome P-450 activity in
cell-free systems [22]. In our study the speci¢c NO scavenger
PTIO [23,24] was unable to prevent desensitization of the
cyclic GMP response indicating that in intact cells, tolerance
develops independently of NO and that NO per se is not a
relevant mediator of nitrate tolerance. This ¢nding correlates
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Fig. 1. E¡ect of a 5-h pretreatment with GTN on subsequent cyclic
GMP accumulation by GTN and Sper/NO in LLC-PK1 cells. Val-
ues are means þ S.E.M. of n = 6 observations. *P6 0.05, vitamin C
vs. vehicle (Student’s two-tailed t-test).
Fig. 2. E¡ect of vitamin C on GTN-induced tolerance in LLC-PK1
cells. Cells were pretreated for 5 h, as indicated, in the absence
(open columns) or presence (hatched and solid columns) of vitamin
C. Values are means þ S.E.M. of n = 6 observations. *P6 0.05 (ordi-
nary one-way ANOVA plus Bonferroni test).
Fig. 3. E¡ect of vitamin C (Vit C, 10 mM), tiron (10 mM), DMSO
(0.2% v/v), and PTIO (30 WM) on tolerance development to GTN
in LLC-PK1 cells. All cells were pretreated for 5 h with GTN (1
WM) in the absence (open column) or presence (solid columns) of
the above mentioned compounds and subsequently challenged with
1 WM GTN. Values are means þ S.E.M. of n = 6 observations.
*P6 0.05 (ordinary one-way ANOVA plus Bonferroni test).
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with clinical observations documenting lack of tolerance in-
duction by spontaneous NO donors such as sodium nitroprus-
side or molsidomine/SIN-1 [25^27].
Superoxide anion radicals have recently been suggested to
cause nitrate tolerance, possibly via reacting with NO to form
peroxynitrite [12]. Peroxynitrite has a shorter half-life than
NO and is a less potent activator of the soluble guanylyl
cyclase/cyclic GMP system [12]. Superoxide originates during
the redox process of nitrate bioactivation [28], and in addition
to forming peroxynitrite is capable of inactivating organic
nitrate converting enzymes such as cytochrome P-450
[13,29]. In the present investigation, however, the tolerance
sparing e¡ect of vitamin C was not reproduced by tiron,
which is widely used as an intracellular superoxide anion scav-
enger [12,16,30]. Similarly, the scavenger of hydroxyl radicals
and peroxynitrite anions DMSO [16,31,32] did not in£uence
desensitization of the cyclic GMP response. These ¢ndings
suggest that reactive oxygen species play no major role in
the development of tolerance and that the preventive potential
of vitamin C comprises mechanisms other than pure radical
scavenging.
In addition to acting as an antioxidant, vitamin C is known
to function as a co-factor in numerous enzymatic reactions
and during processes leading to altered gene expression. No-
tably, vitamin C has been shown to maintain mRNA levels
and to prevent down-regulation of cytochrome P-450-depend-
ent enzymes including those isozymes which are able to cata-
lyze NO formation from organic nitrates [33^35]. In those
studies, preservation of cytochrome P-450 expression by vita-
min C occurred independently of its antioxidant e¡ect [36]
which corresponds with our ¢ndings on tolerance prevention.
That tolerance development may be successfully avoided by
protecting cellular proteins from being down-regulated can
also be concluded from a previous study showing the necessity
of de novo protein synthesis for restoring cellular sensitivity to
organic nitrates in tolerant cells [19].
In summary, our results show that vitamin C has a preven-
tive potential on the development of nitrate tolerance. Its in-
hibitory action on the desensitization of the cyclic GMP re-
sponse to organic nitrates appears not to be related to
antioxidant e¡ects and may result from preserving, at least
in part, the enzymatic bioactivation of organic nitrates.
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